Literature DB >> 19723702

Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function.

Julian M W Quinn1, Shanna Tam, Natalie A Sims, Hasnawati Saleh, Narelle E McGregor, Ingrid J Poulton, John W Scott, Matthew T Gillespie, Bruce E Kemp, B J W van Denderen.   

Abstract

Since AMP-activated protein kinase (AMPK) plays important roles in modulating metabolism in response to diet and exercise, both of which influence bone mass, we examined the influence of AMPK on bone mass in mice. AMPK is an alphabetagamma heterotrimer where the beta subunit anchors the alpha catalytic and gamma regulatory subunits. Germline deletion of either AMPK beta1 or beta2 subunit isoforms resulted in reduced trabecular bone density and mass, but without effects on osteoclast (OC) or osteoblast (OB) numbers, as compared to wild-type littermate controls. We tested whether activating AMPK in vivo would enhance bone density but found AICA-riboside treatment caused a profound loss of trabecular bone volume (49.5%) and density and associated increased OC numbers. Consistent with this, AICA-riboside strongly stimulated OC differentiation in vitro, in an adenosine kinase-dependent manner. OCs and macrophages (unlike OBs) lacked AMPK beta2 subunit expression, and when generated from AMPK beta1(-/-) mice displayed no detectable AMPK activity. Nevertheless, AICA-riboside was equally effective at stimulating OC differentiation from wild-type or beta1(-/-) progenitors, indicating that AMPK is not essential for OC differentiation or the stimulatory action of AICA-riboside. These results show that AMPK is required to maintain normal bone density, but not through bone cell differentiation, and does not mediate powerful osteolytic effects of AICA-riboside.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723702      PMCID: PMC2797037          DOI: 10.1096/fj.09-137158

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  58 in total

Review 1.  Convergence between bone and energy homeostases: leptin regulation of bone mass.

Authors:  Gerard Karsenty
Journal:  Cell Metab       Date:  2006-11       Impact factor: 27.287

Review 2.  Wnt signaling: a key regulator of bone mass.

Authors:  Roland Baron; Georges Rawadi; Sergio Roman-Roman
Journal:  Curr Top Dev Biol       Date:  2006       Impact factor: 4.897

3.  Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine.

Authors:  Dennis T Mangano; Yinghui Miao; Iulia C Tudor; Cynthia Dietzel
Journal:  J Am Coll Cardiol       Date:  2006-05-11       Impact factor: 24.094

4.  Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling.

Authors:  Natalie A Sims; Karen Brennan; Jenny Spaliviero; David J Handelsman; Markus J Seibel
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-10-04       Impact factor: 4.310

Review 5.  Regulating bone growth and development with bone morphogenetic proteins.

Authors:  Phoebe S Leboy
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

6.  The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.

Authors:  John T Price; Julian M W Quinn; Natalie A Sims; Jessica Vieusseux; Kelly Waldeck; Susan E Docherty; Damian Myers; Akira Nakamura; Mark C Waltham; Matthew T Gillespie; Erik W Thompson
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

7.  5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis.

Authors:  Narender Nath; Shailendra Giri; Ratna Prasad; Mohamad Labib Salem; Avtar K Singh; Inderjit Singh
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

8.  Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase.

Authors:  Andrew L Carey; Gregory R Steinberg; S Lance Macaulay; Walter G Thomas; Anna G Holmes; Georg Ramm; Oja Prelovsek; Cordula Hohnen-Behrens; Matthew J Watt; David E James; Bruce E Kemp; Bente K Pedersen; Mark A Febbraio
Journal:  Diabetes       Date:  2006-10       Impact factor: 9.461

9.  The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases.

Authors:  Rebecca L Hurley; Kristin A Anderson; Jeanne M Franzone; Bruce E Kemp; Anthony R Means; Lee A Witters
Journal:  J Biol Chem       Date:  2005-06-24       Impact factor: 5.157

10.  Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling.

Authors:  Gregory R Steinberg; Belinda J Michell; Bryce J W van Denderen; Matthew J Watt; Andrew L Carey; Barbara C Fam; Sofianos Andrikopoulos; Joseph Proietto; Cem Z Görgün; David Carling; Gökhan S Hotamisligil; Mark A Febbraio; Thomas W Kay; Bruce E Kemp
Journal:  Cell Metab       Date:  2006-12       Impact factor: 27.287

View more
  23 in total

1.  AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass.

Authors:  M Shah; B Kola; A Bataveljic; T R Arnett; B Viollet; L Saxon; M Korbonits; C Chenu
Journal:  Bone       Date:  2010-04-24       Impact factor: 4.398

2.  Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity.

Authors:  Sandra Galic; Morgan D Fullerton; Jonathan D Schertzer; Sarah Sikkema; Katarina Marcinko; Carl R Walkley; David Izon; Jane Honeyman; Zhi-Ping Chen; Bryce J van Denderen; Bruce E Kemp; Gregory R Steinberg
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

Review 3.  Targeting AMPK for cardiac protection: opportunities and challenges.

Authors:  Maengjo Kim; Rong Tian
Journal:  J Mol Cell Cardiol       Date:  2010-12-13       Impact factor: 5.000

Review 4.  Bone Cell Bioenergetics and Skeletal Energy Homeostasis.

Authors:  Ryan C Riddle; Thomas L Clemens
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

5.  Genetic deletion of catalytic subunits of AMP-activated protein kinase increases osteoclasts and reduces bone mass in young adult mice.

Authors:  Heeseog Kang; Benoit Viollet; Dianqing Wu
Journal:  J Biol Chem       Date:  2013-03-13       Impact factor: 5.157

Review 6.  Functional characterization of AMP-activated protein kinase signaling in tumorigenesis.

Authors:  Ji Cheng; Tao Zhang; Hongbin Ji; Kaixiong Tao; Jianping Guo; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2016-09-25

Review 7.  Inflammation and intracellular metabolism: new targets in OA.

Authors:  R Liu-Bryan
Journal:  Osteoarthritis Cartilage       Date:  2015-11       Impact factor: 6.576

8.  IGF-I and IGFBP-2 Stimulate AMPK Activation and Autophagy, Which Are Required for Osteoblast Differentiation.

Authors:  Gang Xi; Clifford J Rosen; David R Clemmons
Journal:  Endocrinology       Date:  2015-11-10       Impact factor: 4.736

9.  Mice lacking AMP-activated protein kinase α1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment.

Authors:  J Jeyabalan; M Shah; B Viollet; J P Roux; P Chavassieux; M Korbonits; C Chenu
Journal:  J Endocrinol       Date:  2012-06-14       Impact factor: 4.286

10.  An emerging role for adenosine and its receptors in bone homeostasis.

Authors:  Jack Ham; Bronwen A J Evans
Journal:  Front Endocrinol (Lausanne)       Date:  2012-09-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.